Research and Development Page

Cell Culture Scale-up and Optimization Strategies
Cell manufacture and processing represent major challenges for autologous cell therapy. Northern Therapeutics' research and development efforts are currently focused on streamlining and optimization of the critical steps in this process. The specific optimization strategies include:

i) Improving the methods of harvesting peripheral blood mononuclear cells (PBMNCs) by leukapheresis.
ii) Cell propagation, selection and differentiation strategies. Our current efforts are focused on exploring the use of bioreactors to expand the cells lines in suspension prior to the culture and differentiation steps.
iii) Further optimization of gene transfer by refinement of the Electroporation parameters.

Methods of Cryopreservation and Storage of human EPCs
In order to commercialize our cell-based technology, we need to be able to freeze and store the cells in a manner which ensures cell viability and easy access and utilization of stored cell lines. Potential strategies include the combination use of a source of plasma protein, hydroxyethylstarch (HES) and dimethylsulfoxide (DMSO) to better preserve progenitor cells during cryopreservation.*

* Clapisson G et al. Cryopreservation with hydroxyethylstarch (HES) + dimethylsulfoxide (DMSO) gives better results than DMSO alone. Electronic Journal of Oncology. 1999; 1:97-102.
Pre-Clinical Development: Cell-Based Gene Therapy Program for Lung Regeneration:

Our pre-clinical program represents a continuation of Northern Therapeutics ongoing research and development efforts to examine the potential efficacy of cell-based gene transfer when applied to other vascular and non-vascular pulmonary diseases other than PAH.

Acute Respiratory Distress Syndrome (ARDS)
Cystic Fibrosis (CF)